| Literature DB >> 23833665 |
Marta Rabello Piva1, Lélia Batista DE Souza, Paulo Ricardo Saquete Martins-Filho, Cassiano Francisco Weege Nonaka, Thiago DE Santana Santos, Emanuel Sávio DE Souza Andrade, Diogo Piva.
Abstract
Due to the frequent presence of inflammation in cases of carcinoma and its use as a parameter for the assessment of tumor aggressiveness, the role of inflammation in oral carcinogenesis was investigated. This was performed by evaluating the expression of cellular markers, cytokines and nuclear transcription factors that identify the cells that participate in the antitumor defense in cases of oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC). A semi-quantitative immunohistochemical analysis was performed for the transcription factors cluster of differentiation 8 (CD8), forkhead box P3 (FOXP3), transforming growth factor (TGF)-β, tumor necrosis factor (TNF)-α and nuclear factor κ-light chain enhancer of activated B-cells (NF-κB), in cases of OED and OSCC. CD8, TGF-β, TNF-α and NF-κB participated in the processes of tumor transformation and progression. The presence of inflammatory infiltrate in cases of OED favors the transformation and invasion process when stromal TNF-α and NF-kB are overexpressed, as NF-kB activated by TNF-α during inflammation predisposes the lesion to transformation, functioning as a link between inflammation and cancer. The control of these inflammatory mediators may prevent malignant transformation in the oral cavity.Entities:
Keywords: carcinoma; cytokines; immunohistochemistry; inflammation
Year: 2013 PMID: 23833665 PMCID: PMC3700985 DOI: 10.3892/ol.2013.1302
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Specifications of primary antibodies.
| Antibody | Clone time | Dilution/Incubation | Antigen recovery | Method |
|---|---|---|---|---|
| NF-κB | NF-κB p65 (A) | 1:100/3 h | Citrate | Envision-HRP |
| TNF-α | TNF-α (2C8) | 1:100/Overnight | Pepsin | Envision-HRP |
| TGF-β | TGF-β1 (V) | 1:500/Overnight | Pepsin | Envision-HRP |
| FOXP3 | FOXP3 (H190) | 1:100/Overnight | Tris-EDTA, pH 9.0 | Envision-HRP |
| CD8 | C8/144B | 1:200/60 min | Tris-EDTA, pH 9.0 | SABC |
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA);
Dako (Carpinteria, CA, USA). NF-κB, nuclear factor-κ-light chain enhancer of activated B-cells; TNF-α, tumor necrosis factor-α; TGF-β, transforming growth factor-β; FOXP3, forkhead box P3; CD8, cluster of differentiation 8; HRP, horseradish peroxidase; SABC, Streptavidin-biotin-peroxidase complex.
Figure 1Expression of CD8, forkhead box P3 (FOXP3), tumor growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α) and nuclear factor κ-light chain enhancer of activated B-cells (NF-κB) according to the type of lesion (A), histologic grades of dysplasia (B) and stages of oral squamous cell carcinoma (C). Percentage of immunopositive cells are shown in the hatched columns. Bars represent the standard error of the mean. The expression of CD8 and NF-κB in dysplasia was found to be higher than in carcinoma (*P<0.0001). The expression of stromal TGF-β in stage II carcinoma was found to be higher than in stage I (**P= 0.022).
Correlation between inflammatory infiltrate intensity and expression of cluster of differentiation 8 (CD8), forkhead box P3 (FOXP3), transforming growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α) and nuclear factor-κ-light chain enhancer of activated B-cells (NF-κB).
| Inflammatory infiltrate intensity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| Dysplasia (n=20) | Carcinoma (n=40) | |||||||||||
|
|
| |||||||||||
| Expression (%) | Mild n (%) | Mod. n (%) | Int. n (%) | Total | r | P-value | Mild n (%) | Mod. n (%) | Int. n (%) | Total | r | P-value |
| CD8 | ||||||||||||
| <5 | 2 (40) | 1 (10) | 1 (20) | 4 (20) | 11 (100) | 6 (60) | 10 (50) | 27 (67.5) | ||||
| 5–50 | 2 (40) | 2 (20) | 0 (0) | 4 (20) | 0.391 | NS | 0 (0) | 1 (10) | 2 (10) | 3 (7.5) | 0.365 | <0.05 |
| >50 | 1 (20) | 7 (70) | 4 (80) | 12 (60) | 0 (0) | 2 (20) | 8 (40) | 10 (25) | ||||
| FOXP3 | ||||||||||||
| <5 | 3 (60) | 6 (60) | 2 (40) | 11 (55) | 7 (63.6) | 6 (60) | 11 (57.9) | 24 (60) | ||||
| 5–50 | 1 (20) | 2 (20) | 2 (40) | 5 (25) | 0.109 | NS | 2 (18.2) | 3 (30) | 6 (31.6) | 11 (27.5) | 0.018 | NS |
| >50 | 1 (20) | 2 (20) | 1 (20) | 4 (20) | 2 (18.2) | 1 (10) | 2 (10.5) | 5 (12.5) | ||||
| TGF-β (epithelial cells) | ||||||||||||
| <5 | 1 (20) | 3 (30) | 0 (0) | 4 (20) | 4 (36.4) | 3 (30) | 9 (47.4) | 16 (40) | ||||
| 5–50 | 1 (20) | 4 (40) | 3 (60) | 8 (40) | 0.026 | NS | 3 (27.2) | 5 (50) | 6 (31.6) | 14 (35) | −0.142 | NS |
| >50 | 3 (60) | 3 (40) | 2 (40) | 8 (40) | 4 (36.4) | 2 (20) | 4 (21) | 10 (25) | ||||
| TGF-β (stromal cells) | ||||||||||||
| <5 | 0 (0) | 4 (40) | 0 (0) | 4 (20) | 3 (27.2) | 2 (20) | 2 (10.5) | 7 (17.5) | ||||
| 5–50 | 2 (40) | 1 (10) | 2 (40) | 5 (25) | 0.000 | NS | 4 (36.4) | 3 (30) | 8 (42.1) | 15 (37.5) | 0.189 | NS |
| >50 | 3 (60) | 5 (50) | 3 (60) | 11 (55) | 4 (36.4) | 5 (50) | 9 (47.4) | 18 (45) | ||||
| TNF-α (epithelial cells) | ||||||||||||
| <5 | 3 (60) | 2 (20) | 1 (20) | 6 (30) | 3 (27.3) | 1 (10) | 10 (52.6) | 14 (35) | ||||
| 5–50 | 2 (40) | 4 (40) | 1 (20) | 7 (35) | 0.442 | <0.05 | 6 (54.5) | 6 (60) | 6 (31.6) | 18 (45) | −0.337 | <0.05 |
| >50 | 0 (0) | 4 (40) | 3 (60) | 7 (35) | 2 (18.2) | 3 (30) | 3 (15.8) | 8 (20) | ||||
| TNF-α (stromal cells) | ||||||||||||
| <5 | 2 (40) | 1 (10) | 0 (0) | 3 (15) | 9 (81.8) | 3 (30) | 9 (47.4) | 21 (52.5) | ||||
| 5–50 | 3 (60) | 6 (60) | 1 (20) | 10 (50) | 0.632 | <0.05 | 1 (9.1) | 5 (50) | 6 (31.6) | 12 (30) | 0.383 | <0.05 |
| >50 | 0 (0) | 3 (30) | 4 (80) | 7 (35) | 1 (9.1) | 2 (20) | 4 (21) | 7 (17.5) | ||||
| NF-κB | ||||||||||||
| <5 | 4 (80) | 2 (20) | 0 (0) | 6 (30) | 6 (54.5) | 6 (60) | 8 (42.1) | 20 (50) | ||||
| 5–50 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0.617 | <0.05 | 3 (27.3) | 2 (20) | 10 (52.6) | 15 (37.5) | 0.046 | NS |
| >50 | 1 (20) | 8 (80) | 5 (100) | 14 (70) | 2 (18.2) | 2 (20) | 1 (5.3) | 5 (12.5) | ||||
Spearman rank correlation coefficient.
P<0.05, statistically significant; NS, not significant. Mod., moderate; Int., intense.